Research > ETFs > ETF / ETP Commentary > 

GINN: an Innovative Road to Disruptive Growth

Owing to the much-documented rise of 10-year Treasury yields earlier this year, exchange traded funds focusing on disruptive growth equities flailed at the start of 2021.The Goldman Sachs Innovate Equity ETF (GINN) got caught up in that struggle. To be fair, GINN wasn’t the only offender. Broadly speaking, tech and growth stocks encountered some headwinds due to rising inflation. While some market participants confuse inflation with expansion, the economy is in a recovery phase right now, which is an unusual point in the cycle for growth strategies to perform well.However, as the economic cycle moves from recovery to expansion, GDP growth rates slow — a scenario that some market observers are already wagering on happening in the second half of 2021. Slower economic growth is usually a favorable backdrop for growth funds, including disruptive fare like GINN. As things stand today, GINN is already cobbling together some momentum.“So, first of all, second-quarter earnings generally were pretty strong across the entire s(tech) sector,” says Morningstar analyst Dave Sekera. “And we’re looking at pretty strong returns again, here, coming up in the third quarter. Now, tech did have a little bit of a tough time at the beginning of the year when interest rates were going up.”The $492.48 million GINN allocates 33.4% of its weight to tech stocks, by far its largest sector exposure.Macro Environment Could Benefit GINNShould inflation ease and 10-year Treasury yields hold steady or decline, GINN stands out as an ETF poised to benefit from both of those scenarios.“With interest rates actually coming back down this summer, that took a lot of the pressure off of what we consider to be those long duration stocks, those growth stocks of which technology has a lot of those names in there as well. So, with that pressure being off, that certainly helped the sector as well,” adds Sekera.While the technology sector is modestly overvalued today, that scenario isn’t particularly relative to the sector’s past bouts with elevated multiples. Additionally, GINN has avenues for augmenting that situation.For example, some disruptive healthcare stocks, including biotechnology names, are scuffling this year, and that opens the door to valuation opportunities. Healthcare is GINN’s second-largest sector allocation at north of 18%.According to Morningstar’s Sekera, the communication services sector is undervalued today, and that includes high fliers Alphabet (NASDAQ:GOOG) and Facebook (NASDAQ:FB). Those stocks combine for 4.1% of GINN’s weight, and the sector commands an allocation of 13.3% in the ETF.For more news, information, and strategy, visit the Future ETFs Channel.

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.